Skip to content

AMRX · Amneal Pharmaceuticals, Inc.

Healthcare · +2.0% on Oct 27

☆ Add to watchlist

Updated Oct 29 · 7 feeds behind: Congress trades, 12 days, and 6 more · Every feed →

On this page

The market view

Price chart

The interactive AMRX chart (by TradingView) loads here.

Our take

5 rules fired on AMRX

In short: none of these rules has solid or some evidence yet, so they show no clear lean on AMRX.

How each did in past tests, against similar stocks over 3 months. Past results don't predict future ones.

All 5 rules
The 0–100 score for AMRX, and which of these rules are open on it right now
Members see one number for how strongly these rules agree on AMRX, and the day each rule fired. Better-tested rules count more, and so do different kinds of filings that point the same way.
See pricing →
Already a member? Sign in

Compare with this company’s history

Is disclosure activity unusual?

See how many different insiders or members of Congress reported purchases or sales of AMRX. Each bar covers 28 days, by disclosure date. Several trades by one person count once in each group and period.

Latest period: Oct 1, 2026–Oct 28, 2026 · UTC dates · today is excluded

Insider purchases

Short history

Only 1 earlier period is on file to compare with. We need at least 6 full periods before calling a count unusual.

Latest 28 days
0
Earlier median
0
Earlier range
0–0
Distinct filers per 28 daysScale: 0–1
Oct 30, 2025Oct 28, 2026
Earlier periodsLatest 28 daysEarlier median 0Limited or missing history

Who appears in the latest period?

No named filers on file for this period.

Up to three filers; one example disclosure each.

Inspect this period’s filings

The history behind this view

First stored company disclosure: Aug 13, 2026. Newest disclosure across this feed: Oct 27, 2026.

Earlier periods in the comparison: 1. Outlined periods are missing data, so they are left out of the comparison. The chart scale changes with the category.

Exact counts, dates and filings for all four categories
Insider purchases · Short history

Only 1 earlier period is on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–0.

Insider purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 30, 2025–Nov 26, 2025—Unavailable
Nov 27, 2025–Dec 24, 2025—Unavailable
Dec 25, 2025–Jan 21, 2026—Unavailable
Jan 22, 2026–Feb 18, 2026—Unavailable
Feb 19, 2026–Mar 18, 2026—Unavailable
Mar 19, 2026–Apr 15, 2026—Unavailable
Apr 16, 2026–May 13, 2026—Unavailable
May 14, 2026–Jun 10, 2026—Unavailable
Jun 11, 2026–Jul 8, 2026—Unavailable
Jul 9, 2026–Aug 5, 2026—Unavailable
Aug 6, 2026–Sep 2, 20260Partial; excluded
Sep 3, 2026–Sep 30, 20260Within stored history
Oct 1, 2026–Oct 28, 2026Latest period0Within stored history
Insider sales · Short history

Only 1 earlier period is on file to compare with. We need at least 6 full periods before calling a count unusual. Earlier median: 0; range: 0–0.

Insider sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 30, 2025–Nov 26, 2025—Unavailable
Nov 27, 2025–Dec 24, 2025—Unavailable
Dec 25, 2025–Jan 21, 2026—Unavailable
Jan 22, 2026–Feb 18, 2026—Unavailable
Feb 19, 2026–Mar 18, 2026—Unavailable
Mar 19, 2026–Apr 15, 2026—Unavailable
Apr 16, 2026–May 13, 2026—Unavailable
May 14, 2026–Jun 10, 2026—Unavailable
Jun 11, 2026–Jul 8, 2026—Unavailable
Jul 9, 2026–Aug 5, 2026—Unavailable
Aug 6, 2026–Sep 2, 20263Partial; excluded
Sep 3, 2026–Sep 30, 20260Within stored history
Oct 1, 2026–Oct 28, 2026Latest period0Within stored history
Congress purchases · Source needs an update

The feed’s newest disclosure is too old for a current comparison. Counts show only the records already stored. Earlier median: —; range: unavailable.

Congress purchases: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 30, 2025–Nov 26, 2025—Unavailable
Nov 27, 2025–Dec 24, 2025—Unavailable
Dec 25, 2025–Jan 21, 2026—Unavailable
Jan 22, 2026–Feb 18, 2026—Unavailable
Feb 19, 2026–Mar 18, 2026—Unavailable
Mar 19, 2026–Apr 15, 2026—Unavailable
Apr 16, 2026–May 13, 2026—Unavailable
May 14, 2026–Jun 10, 2026—Unavailable
Jun 11, 2026–Jul 8, 2026—Unavailable
Jul 9, 2026–Aug 5, 2026—Unavailable
Aug 6, 2026–Sep 2, 2026—Unavailable
Sep 3, 2026–Sep 30, 2026—Unavailable
Oct 1, 2026–Oct 28, 2026Latest period—Unavailable
Congress sales · Source needs an update

The feed’s newest disclosure is too old for a current comparison. Counts show only the records already stored. Earlier median: —; range: unavailable.

Congress sales: distinct filers in stored disclosures
Period and filingsFilersHistory
Oct 30, 2025–Nov 26, 2025—Unavailable
Nov 27, 2025–Dec 24, 2025—Unavailable
Dec 25, 2025–Jan 21, 2026—Unavailable
Jan 22, 2026–Feb 18, 2026—Unavailable
Feb 19, 2026–Mar 18, 2026—Unavailable
Mar 19, 2026–Apr 15, 2026—Unavailable
Apr 16, 2026–May 13, 2026—Unavailable
May 14, 2026–Jun 10, 2026—Unavailable
Jun 11, 2026–Jul 8, 2026—Unavailable
Jul 9, 2026–Aug 5, 2026—Unavailable
Aug 6, 2026–Sep 2, 2026—Unavailable
Sep 3, 2026–Sep 30, 2026—Unavailable
Oct 1, 2026–Oct 28, 2026Latest period—Unavailable
How to read this comparison

The median is the middle count in up to 12 earlier, non-overlapping 28-day periods; the range runs from the smallest to the largest count. The latest period is excluded from both. A comparison needs at least 6 earlier periods, including 3 with activity. The feed’s latest disclosure must be within 7 days of the current period’s end. This freshness check does not verify complete collection.

Insiders include individuals and reporting entities; only purchase and sale codes enter this view. Congress counts reporting members, including their disclosed family transactions. The same filer can appear in purchases and sales, so these categories should not be added into a net count.

These are stored disclosures, not a complete measure of trading. Reporting delays and collection gaps can change the comparison. More activity does not identify a motive or predict a stock’s return.

Company timeline

What has been happening?

May 1, 2026–Oct 27, 2026. Select a month in a category to inspect its records.

Company filings

Insiders

FDA & trials

Owners & lobbying

Company filings · Oct 2026

  1. Filed
All 27 records in this snapshot
  1. Filed
  2. Record date
    FDA approval: Exenatide ↗

    ANDA · supplement

  3. Record date
  4. Record date
    FDA approval: Anda218217 ↗

    ANDA · new application

  5. Disclosed
    John Kiely · Sale

    Transaction dated Aug 13, 2026

  6. Disclosed
    Jason B. Daly · Sale

    Transaction dated Aug 12, 2026

  7. Disclosed
    Jason B. Daly · Sale

    Transaction dated Aug 11, 2026

  8. Disclosed
    Nikita Shah · Sale

    Transaction dated Aug 12, 2026

  9. Filed
  10. Filed
  11. Filed
  12. Filed
    Patel Chintu ↗

    13D amendment

  13. Filed
    Patel Chirag K. ↗

    13D amendment

  14. Filed
  15. Filed
  16. Filed
  17. Filed
  18. Filed
  19. Filed
  20. Record date
  21. Record date
  22. Record date
    Lobbying for Amneal Pharmaceuticals ↗

    $190K · by Amneal Pharmaceuticals

  23. Record date
  24. Record date
    Lobbying for Amneal Pharmaceuticals, Inc. ↗

    $60K · by Tarplin, Downs & Young, LLC

  25. Filed
  26. Record date
  27. Record date

Month counts include every record on file. The lists show the newest records on this page. A dash means none on file that month. Trades use disclosure dates; contract dates follow the source record. Nearby events do not establish the cause of a price move.

Who's buying and selling · last 90 days

Congress

No Congress trades on AMRX disclosed in the last 90 days.

See every Congress trade on AMRX →

Company insiders

0 buys · 3 sells (4 filed lots) · $7.2M sold

  1. ▼ SELLJohn Kiely DirectorAMRX Amneal Pharmaceuticals, Inc.$882Kdisclosed Aug 14 · filed 1 day after the trade
  2. ▼ SELLJason B. Daly EVP, Chief Legal OfficerAMRX Amneal Pharmaceuticals, Inc.$3.7Mdisclosed Aug 13 · filed 1 day after the trade
  3. ▼ SELLJason B. Daly EVP, Chief Legal OfficerAMRX Amneal Pharmaceuticals, Inc.$117Kdisclosed Aug 13 · filed 2 days after the trade
  4. ▼ SELLNikita Shah Executive Vice PresidentAMRX Amneal Pharmaceuticals, Inc.$2.6Mdisclosed Aug 13 · filed 1 day after the trade
See every insider trade on AMRX →

Big holders (Schedule 13D / 13G): 3 filings in the last 90 days · newest: Patel Chintu (13D amendment), Aug 12, 2026 ↗

Filings & events

Company filings (8-K) 74

Events the company must report to the SEC within days — results, deals, departures, restatements.

What it files 8-Ks about

  • Shared information with investors · item 7.0116
  • Quarterly or yearly results · item 2.0214
  • Signed a major agreement · item 1.016
  • Took on new debt · item 2.034
  • Other events · item 8.014
  • Shareholder vote results · item 5.073

Filing red flags 73

Warning signs in the company's own SEC filings — going-concern doubts, control weaknesses, staff comment letters, late filings, restatements, Wells notices, clinical holds, dividend cuts.

FDA and clinical trials 178

Drug approvals, recalls, clinical-trial updates and FDA advisory meetings.

Lobbying 55

Lobbying reports filed with the Senate for the company.

$9.8M across 55 reports

Issues named in the most reports

  • Health Issues 42
  • Manufacturing 13
  • Budget/Appropriations 3
  • Medicare/Medicaid 1

Planned insider sales (Form 144) 35

Notices insiders file before they sell certain shares, such as ones they got straight from the company.

4 in the last 90 days · 35 notices on file

The notices on file don't give the sale's size; each sale shows up under company insiders once it is reported.

5% owners (13D / 13G) 12

Investors who reported owning 5% or more — 13D for owners who may push for changes, 13G for owners who just hold.

Push for changes, or just hold?

  • 13D, may push for changes: 9 filings
  • 13G, just holds: 3 filings

Filed most: Patel Dipan (3) · Patel Chintu (2) · Patel Chirag K. (2) · Patel Tushar Bhikhubhai (2)

Biggest named funds (13F)

The largest AMRX holdings among the well-known funds whose quarterly 13F filings we read — opens here.

Every disclosed trade on AMRX

  1. ▼ SELLJohn Kiely DirectorAMRX Amneal Pharmaceuticals, Inc.$882Kdisclosed Aug 14 · filed 1 day after the trade
  2. ▼ SELLJason B. Daly EVP, Chief Legal OfficerAMRX Amneal Pharmaceuticals, Inc.$3.7Mdisclosed Aug 13 · filed 1 day after the trade
  3. ▼ SELLJason B. Daly EVP, Chief Legal OfficerAMRX Amneal Pharmaceuticals, Inc.$117Kdisclosed Aug 13 · filed 2 days after the trade
  4. ▼ SELLNikita Shah Executive Vice PresidentAMRX Amneal Pharmaceuticals, Inc.$2.6Mdisclosed Aug 13 · filed 1 day after the trade
See the trades on AMRX in the feed →
People & votes

Which members of Congress traded AMRX, sponsored bills that touch it and voted on them — opens here.